ClinicalTrials.gg
CompletedNCT00940017Updated Feb 9, 2010Results posted

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

A Phase 4 interventional study of anidulafungin and voriconazole in Aspergillosis and Candidemia, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-02-09.

Sponsored by Pfizer · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.

Enrollment
8th of 17
24 · median 24
Started
2008
with 2 others
Phase 4
4 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
6 of 17
Pfizer

Among the 17 studies testing voriconazole in Aspergillosis, this one is the 8th largest by enrollment, is one of 3 that started in 2008, is one of 4 in phase 4, and was the 10th registered.

Aspergillosis

134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.

Browse Aspergillosis studies →

Open to participants now

None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →

About voriconazole

Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing voriconazole in Aspergillosis as a file.
02

Study summary

The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.

03

Conditions studied

  • Aspergillosis
  • Candidemia

Keywords

  • PK
  • fungal infection
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult subjects willing to comply with the study requirement.

Exclusion criteria

Exclusion Criteria:

  • Clinical significant disease.
  • Sensitive to study medication.
  • Not willing to comply with the study requirement.
05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1

    Drug: anidulafungin and voriconazole

Interventions

  • Druganidulafungin and voriconazole

    Drug pages: Anidulafungin · Voriconazole

    Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.

06

What researchers measure

Primary outcomes

  1. Plasma Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)

    Cmax = maximum observed plasma concentration; measured in micrograms per milliliter (ug/mL). Observed directly from the data. Collected on Day 3.

    Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion

  2. Plasma PK: Time to Reach Maximum Plasma Concentration (Tmax)

    Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. Collected on Day 3.

    Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion

  3. Plasma PK: Area Under the Curve From Time Zero to Time = Tau (AUCtau)

    AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole; measured as micrograms times hours per milliliter (ug\*hr/mL). Collected on Day 3.

    Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion

  4. Plasma PK: Plasma Elimination Half-life (t1/2)

    t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Collected on Day 3.

    Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion

  5. Plasma PK: Total Clearance (CL Total)

    CL total = total clearance calculated as dose divided by AUCt; measured as milliliters per minute (mL/min). Collected on Day 3.

    Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion

  6. Plasma PK: Volume of Distribution at Steady-state (Vss)

    Vss = volume of distribution at steady-state; measured as liters (L). Calculated as (CL multiplied by mean residence time extrapolated to infinity \[MRTinf\]). MRTinf = \[(AUMCt plus t (AUCinf minus AUCt)) divided by AUCt\] minus (infusion time divided by 2); AUMCt = area under the first moment curve from time zero to time t; AUCinf = area under the plasma concentration-time curve extrapolated to infinity.

    Time frame: 100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion

  7. Epithelial Lining Fluid (ELF) PK: Cmax

    Cmax=maximum observed plasma concentration. ELF collected by bronchoscopy and bronchoalveolar lavage (BAL) Day 3; determined from BAL sample using urea dilution method: \[Drug ELF\]=\[Drug BAL\] multiplied by \[Urea SERUM\] divided by \[Urea BAL\]. Drug ELF=anidulafungin or voriconazole (drug) concentration in ELF corrected for dilution; Drug BAL=assayed drug concentration in BAL; Urea SERUM and Urea BAL simultaneously collected. Summary parameters derived using average data for all subjects; associated to a single subject for reporting purposes (mean with standard deviation not calculated).

    Time frame: 4, 8, 12, 24 hours after start of infusion

  8. ELF PK: Tmax

    Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. ELF collected by bronchoscopy and BAL on Day 3.

    Time frame: 4, 8, 12, 24 hours after start of infusion

  9. ELF PK: AUCtau

    AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole. ELF collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).

    Time frame: 4, 8, 12, 24 hours after start of infusion

  10. ELF PK: t1/2

    t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. ELF collected by bronchoscopy and BAL on Day 3.

    Time frame: 4, 8, 12, 24 hours after start of infusion

  11. Alveolar Macrophages (AM): Cmax

    Cmax = maximum observed plasma concentration; observed directly from the data. AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).

    Time frame: 4, 8, 12, 24 hours after start of infusion

  12. AM: Tmax

    Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. AM collected by bronchoscopy and BAL on Day 3.

    Time frame: 4, 8, 12, 24 hours after start of infusion

  13. AM: AUCtau

    AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole. AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).

    Time frame: 4, 8, 12, 24 hours after start of infusion

  14. AM: t1/2

    t1/2 = terminal elimination half-life in hours; Loge(2)Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AM collected by bronchoscopy and BAL on Day 3.

    Time frame: 4, 8, 12, 24 hours after start of infusion

  15. Overall Drug Penetration Ratio in ELF

    ELF collected by bronchoscopy and BAL on Day 3. ELF to plasma penetration ratio calculated by dividing area under the plasma concentration-time profile (AUC) in ELF by AUC in plasma from 20 subjects where t is 24 hours for anidulafungin and 12 hours for voriconazole. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).

    Time frame: 4, 8, 12, 24 hours after start of infusion

  16. Concentration Ratio in ELF to Plasma

    Concentration ratio in ELF to plasma determined by a point estimate within each subject at the time-point where ELF data was available.

    Time frame: 4, 8, 12, 24 hours after start of infusion

07

Results

Posted Feb 9, 2010

Participant flow

Participant flow — Overall Study
MilestoneAnidulafungin and Voriconazole
Started24
Subjects treated21
Completed20
Not completed4
Withdrew: Did not meet entrance criteria3
Withdrew: Adverse event1

Outcome measures

PrimaryPlasma Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)

Cmax = maximum observed plasma concentration; measured in micrograms per milliliter (ug/mL). Observed directly from the data. Collected on Day 3.

Time frame:
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Reported as:
Mean · ug/mL
Plasma Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)
ug/mLAnidulafungin and Voriconazole
Anidulafungin6.56 ± 1.62
Voriconazole5.32 ± 1.82
PrimaryPlasma PK: Time to Reach Maximum Plasma Concentration (Tmax)

Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. Collected on Day 3.

Time frame:
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Reported as:
Median · hours
Plasma PK: Time to Reach Maximum Plasma Concentration (Tmax)
hoursAnidulafungin and Voriconazole
Anidulafungin1.93 (1.70 to 2.17)
Voriconazole1.74 (1.67 to 2.05)
PrimaryPlasma PK: Area Under the Curve From Time Zero to Time = Tau (AUCtau)

AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole; measured as micrograms times hours per milliliter (ug\*hr/mL). Collected on Day 3.

Time frame:
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Reported as:
Mean · ug*hr/mL
Plasma PK: Area Under the Curve From Time Zero to Time = Tau (AUCtau)
ug*hr/mLAnidulafungin and Voriconazole
Anidulafungin101 ± 21.8
Voriconazole39.5 ± 19.8
PrimaryPlasma PK: Plasma Elimination Half-life (t1/2)

t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Collected on Day 3.

Time frame:
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Reported as:
Mean · hours
Plasma PK: Plasma Elimination Half-life (t1/2)
hoursAnidulafungin and Voriconazole
Anidulafungin (n=18)20.8 ± 3.06
Voriconazole (n=15)6.94 ± 2.10
PrimaryPlasma PK: Total Clearance (CL Total)

CL total = total clearance calculated as dose divided by AUCt; measured as milliliters per minute (mL/min). Collected on Day 3.

Time frame:
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Reported as:
Mean · mL/min
Plasma PK: Total Clearance (CL Total)
mL/minAnidulafungin and Voriconazole
Anidulafungin17.1 ± 3.04
Voriconazole172 ± 86.2
PrimaryPlasma PK: Volume of Distribution at Steady-state (Vss)

Vss = volume of distribution at steady-state; measured as liters (L). Calculated as (CL multiplied by mean residence time extrapolated to infinity \[MRTinf\]). MRTinf = \[(AUMCt plus t (AUCinf minus AUCt)) divided by AUCt\] minus (infusion time divided by 2); AUMCt = area under the first moment curve from time zero to time t; AUCinf = area under the plasma concentration-time curve extrapolated to infinity.

Time frame:
100 minutes (end of infusion), 2, 4, 8, 12, 24 hours after start of infusion
Reported as:
Mean · L
Plasma PK: Volume of Distribution at Steady-state (Vss)
LAnidulafungin and Voriconazole
Anidulafungin (n=18)30.8 ± 6.84
Voriconazole (n=15)110 ± 34.0
PrimaryEpithelial Lining Fluid (ELF) PK: Cmax

Cmax=maximum observed plasma concentration. ELF collected by bronchoscopy and bronchoalveolar lavage (BAL) Day 3; determined from BAL sample using urea dilution method: \[Drug ELF\]=\[Drug BAL\] multiplied by \[Urea SERUM\] divided by \[Urea BAL\]. Drug ELF=anidulafungin or voriconazole (drug) concentration in ELF corrected for dilution; Drug BAL=assayed drug concentration in BAL; Urea SERUM and Urea BAL simultaneously collected. Summary parameters derived using average data for all subjects; associated to a single subject for reporting purposes (mean with standard deviation not calculated).

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Number · average concentration (ug/mL)
Epithelial Lining Fluid (ELF) PK: Cmax
average concentration (ug/mL)Anidulafungin and Voriconazole
Anidulafungin1.13
Voriconazole48.3
PrimaryELF PK: Tmax

Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. ELF collected by bronchoscopy and BAL on Day 3.

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Number · hours
ELF PK: Tmax
hoursAnidulafungin and Voriconazole
Anidulafungin24.0
Voriconazole4.0
PrimaryELF PK: AUCtau

AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole. ELF collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Number · average concentration (ug*hr/mL)
ELF PK: AUCtau
average concentration (ug*hr/mL)Anidulafungin and Voriconazole
Anidulafungin21.9
Voriconazole282
PrimaryELF PK: t1/2

t1/2 = terminal elimination half-life in hours; Loge(2)/Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. ELF collected by bronchoscopy and BAL on Day 3.

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Number · hours

No measurements were reported for this outcome.

PrimaryAlveolar Macrophages (AM): Cmax

Cmax = maximum observed plasma concentration; observed directly from the data. AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Number · average concentration (ug/mL)
Alveolar Macrophages (AM): Cmax
average concentration (ug/mL)Anidulafungin and Voriconazole
Anidulafungin103
Voriconazole20.5
PrimaryAM: Tmax

Tmax = time (hours) to maximum plasma concentration (Cmax). Observed directly from data as time of first occurrence. AM collected by bronchoscopy and BAL on Day 3.

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Number · hours
AM: Tmax
hoursAnidulafungin and Voriconazole
Anidulafungin24
Voriconazole4.0
PrimaryAM: AUCtau

AUCtau = area under the plasma concentration-time profile from time zero (0) to time = t (AUCt), the dosing interval, where t is 24 hours for anidulafungin and 12 hours for voriconazole. AM collected by bronchoscopy and BAL on Day 3. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Number · average concentration (ug*hr/mL)
AM: AUCtau
average concentration (ug*hr/mL)Anidulafungin and Voriconazole
Anidulafungin1430
Voriconazole178
PrimaryAM: t1/2

t1/2 = terminal elimination half-life in hours; Loge(2)Kel, where Kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AM collected by bronchoscopy and BAL on Day 3.

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Number · hours

No measurements were reported for this outcome.

PrimaryOverall Drug Penetration Ratio in ELF

ELF collected by bronchoscopy and BAL on Day 3. ELF to plasma penetration ratio calculated by dividing area under the plasma concentration-time profile (AUC) in ELF by AUC in plasma from 20 subjects where t is 24 hours for anidulafungin and 12 hours for voriconazole. Summary parameters were derived using average data for all subjects and associated to a single subject for reporting purposes (mean with standard deviation was not calculated).

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Number · average ELF to plasma ratio
Overall Drug Penetration Ratio in ELF
average ELF to plasma ratioAnidulafungin and Voriconazole
Anidulafungin0.22
Voriconazole7.14
PrimaryConcentration Ratio in ELF to Plasma

Concentration ratio in ELF to plasma determined by a point estimate within each subject at the time-point where ELF data was available.

Time frame:
4, 8, 12, 24 hours after start of infusion
Reported as:
Mean · ratio
Concentration Ratio in ELF to Plasma
ratioAnidulafungin and Voriconazole
Anidulafungin 4 hours0.15 ± 0.02
Anidulafungin 8 hours0.15 ± 0.07
Anidulafungin 12 hours0.20 ± 0.09
Anidulafungin 24 hours0.38 ± 0.14
Voriconazole 4 hours9.50 ± 2.31
Voriconazole 8 hours4.93 ± 2.79
Voriconazole 12 hours7.68 ± 3.41

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anidulafungin and Voriconazole—0/21 (0%)15/21 (71.4%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAnidulafungin and Voriconazole
HeadacheNervous system disorders6/21
Influenza like illnessGeneral disorders4/21
Visual impairmentEye disorders3/21
PhotophobiaEye disorders2/21
VomitingGastrointestinal disorders2/21
NauseaGastrointestinal disorders1/21
HypersensitivityImmune system disorders1/21
Liver function test abnormalInvestigations1/21
Hallucination, visualPsychiatric disorders1/21
InsomniaPsychiatric disorders1/21

Baseline characteristics

Age Continuous
Age Continuous(years)Anidulafungin and Voriconazole
Mean27.3 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Anidulafungin and Voriconazole
Female5
Male19
08

Study locations

1 site
  • Pfizer Investigational Site
    Hartford, Connecticut 06102, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2009
First posted
Jul 15, 2009
Start
Sep 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Feb 9, 2010
Last update
Feb 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00940017
Lead sponsor
Pfizer
First posted
Jul 15, 2009
Start date
Sep 2008
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Feb 9, 2010
Last update
Feb 9, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anidulafungin · Voriconazole

Start the discussion